TY - JOUR
T1 - Alternative genomic diagnoses for individuals with a clinical diagnosis of Dubowitz syndrome
AU - Care4Rare Consortium
AU - Centers for Mendelian Genomics
AU - Dyment, David A.
AU - O'Donnell-Luria, Anne
AU - Agrawal, Pankaj B.
AU - Coban Akdemir, Zeynep
AU - Aleck, Kyrieckos A.
AU - Antaki, Danny
AU - Al Sharhan, Hind
AU - Au, Ping Yee B.
AU - Aydin, Hatip
AU - Beggs, Alan H.
AU - Bilguvar, Kaya
AU - Boerwinkle, Eric
AU - Brand, Harrison
AU - Brownstein, Catherine A.
AU - Buyske, Steve
AU - Chodirker, Bernard
AU - Choi, Jungmin
AU - Chudley, Albert E.
AU - Clericuzio, Carol L.
AU - Cox, Gerald F.
AU - Curry, Cynthia
AU - de Boer, Elke
AU - de Vries, Bert B.A.
AU - Dunn, Kathryn
AU - Dutmer, Cullen M.
AU - England, Eleina M.
AU - Fahrner, Jill A.
AU - Geckinli, Bilgen B.
AU - Genetti, Casie A.
AU - Gezdirici, Alper
AU - Gibson, William T.
AU - Gleeson, Joseph G.
AU - Greenberg, Cheryl R.
AU - Hall, April
AU - Hamosh, Ada
AU - Hartley, Taila
AU - Jhangiani, Shalini N.
AU - Karaca, Ender
AU - Kernohan, Kristin
AU - Lauzon, Julie L.
AU - Lewis, M. E.Suzanne
AU - Lowry, R. Brian
AU - López-Giráldez, Francesc
AU - Matise, Tara C.
AU - McEvoy-Venneri, Jennifer
AU - McInnes, Brenda
AU - Mhanni, Aziz
AU - Garcia Minaur, Sixto
AU - Moilanen, Jukka
AU - Nguyen, An
N1 - Funding Information:
Boston Children's Hospital OFD Career Development Award; Canadian Institutes of Health Research; Children's Hospital of Eastern Ontario Foundation; Dutch Organization for Health Research and Development Grant, Grant/Award Numbers: 912‐12‐109, 917‐86‐319; Estonian Research Council, Grant/Award Numbers: PRG471, PUTJD827; Genome Alberta, British Columbia and Quebec; Genome Canada and the Ontario Genomics Institute, Grant/Award Number: OGI‐147; National Heart, Lung, and Blood Institute (NHLBI); National Human Genome Research Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI) Awards/National Eye Institute (NEI), Grant/Award Numbers: UM1 HG006493, UM1 HG006504, UM1 HG006542, UM1 HG008900; National Human Genome Research Institute, Grant/Award Numbers: R01 HG009141, K08 HG008986, U24 HG008956; National Institute of Child Health and Human Development (NICHD), Grant/Award Number: K12 HD052896; National Organization of Rare Disorders (NORD); Ontario Research Fund Funding information
Funding Information:
The authors would like to acknowledge the families and individuals that have provided samples. The Care4Rare Canada Consortium work was funded by Genome Canada and the Ontario Genomics Institute (OGI‐147), the Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Genome Quebec, and Children's Hospital of Eastern Ontario Foundation. Funding was also provided by the National Organization of Rare Disorders (NORD). The Baylor Hopkins Center for Mendelian Genomics, Broad Institute Harvard Center for Mendelian Genomics, University of Washington Center for Mendelian Genomics, and Yale Center for Mendelian Genomics were funded by the National Human Genome Research Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI)/National Eye Institute (NEI) awards UM1 HG006542, UM1 HG008900, UM1 HG006493, and UM1 HG006504, respectively. Analysis was additionally supported by NHGRI grant R01 HG009141. Funds were also provided under the NHLBI under the Trans‐Omics for Precision Medicine Program (TOPMed). The GSP Coordinating Center (NHGRI U24 HG008956) contributed to cross‐program scientific initiatives and provided logistical and general study coordination. A. H. O.‐L. was supported by National Institute of Child Health and Human Development (NICHD) K12 HD052896 and a Boston Children's Hospital OFD Career Development Award. J. E. P. was supported by NHGRI K08 HG008986. K. Õ. and S. P. are supported by Estonian Research Council grants PRG471 and PUTJD827. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was financially supported by grants from the Dutch Organization for Health Research and Development (ZON‐MW grants 917‐86‐319 and 912‐12‐109 to B. B. A. d. V.).
Funding Information:
The authors would like to acknowledge the families and individuals that have provided samples. The Care4Rare Canada Consortium work was funded by Genome Canada and the Ontario Genomics Institute (OGI-147), the Canadian Institutes of Health Research, Ontario Research Fund, Genome Alberta, Genome British Columbia, Genome Quebec, and Children's Hospital of Eastern Ontario Foundation. Funding was also provided by the National Organization of Rare Disorders (NORD). The Baylor Hopkins Center for Mendelian Genomics, Broad Institute Harvard Center for Mendelian Genomics, University of Washington Center for Mendelian Genomics, and Yale Center for Mendelian Genomics were funded by the National Human Genome Research Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI)/National Eye Institute (NEI) awards UM1 HG006542, UM1 HG008900, UM1 HG006493, and UM1 HG006504, respectively. Analysis was additionally supported by NHGRI grant R01 HG009141. Funds were also provided under the NHLBI under the Trans-Omics for Precision Medicine Program (TOPMed). The GSP Coordinating Center (NHGRI U24 HG008956) contributed to cross-program scientific initiatives and provided logistical and general study coordination. A. H. O.-L. was supported by National Institute of Child Health and Human Development (NICHD) K12 HD052896 and a Boston Children's Hospital OFD Career Development Award. J. E. P. was supported by NHGRI K08 HG008986. K. ?. and S. P. are supported by Estonian Research Council grants PRG471 and PUTJD827. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was financially supported by grants from the Dutch Organization for Health Research and Development (ZON-MW grants 917-86-319 and 912-12-109 to B. B. A. d. V.).
Publisher Copyright:
© 2020 Wiley Periodicals LLC
PY - 2021/1
Y1 - 2021/1
N2 - Dubowitz syndrome (DubS) is considered a recognizable syndrome characterized by a distinctive facial appearance and deficits in growth and development. There have been over 200 individuals reported with Dubowitz or a “Dubowitz-like” condition, although no single gene has been implicated as responsible for its cause. We have performed exome (ES) or genome sequencing (GS) for 31 individuals clinically diagnosed with DubS. After genome-wide sequencing, rare variant filtering and computational and Mendelian genomic analyses, a presumptive molecular diagnosis was made in 13/27 (48%) families. The molecular diagnoses included biallelic variants in SKIV2L, SLC35C1, BRCA1, NSUN2; de novo variants in ARID1B, ARID1A, CREBBP, POGZ, TAF1, HDAC8, and copy-number variation at1p36.11(ARID1A), 8q22.2(VPS13B), Xp22, and Xq13(HDAC8). Variants of unknown significance in known disease genes, and also in genes of uncertain significance, were observed in 7/27 (26%) additional families. Only one gene, HDAC8, could explain the phenotype in more than one family (N = 2). All but two of the genomic diagnoses were for genes discovered, or for conditions recognized, since the introduction of next-generation sequencing. Overall, the DubS-like clinical phenotype is associated with extensive locus heterogeneity and the molecular diagnoses made are for emerging clinical conditions sharing characteristic features that overlap the DubS phenotype.
AB - Dubowitz syndrome (DubS) is considered a recognizable syndrome characterized by a distinctive facial appearance and deficits in growth and development. There have been over 200 individuals reported with Dubowitz or a “Dubowitz-like” condition, although no single gene has been implicated as responsible for its cause. We have performed exome (ES) or genome sequencing (GS) for 31 individuals clinically diagnosed with DubS. After genome-wide sequencing, rare variant filtering and computational and Mendelian genomic analyses, a presumptive molecular diagnosis was made in 13/27 (48%) families. The molecular diagnoses included biallelic variants in SKIV2L, SLC35C1, BRCA1, NSUN2; de novo variants in ARID1B, ARID1A, CREBBP, POGZ, TAF1, HDAC8, and copy-number variation at1p36.11(ARID1A), 8q22.2(VPS13B), Xp22, and Xq13(HDAC8). Variants of unknown significance in known disease genes, and also in genes of uncertain significance, were observed in 7/27 (26%) additional families. Only one gene, HDAC8, could explain the phenotype in more than one family (N = 2). All but two of the genomic diagnoses were for genes discovered, or for conditions recognized, since the introduction of next-generation sequencing. Overall, the DubS-like clinical phenotype is associated with extensive locus heterogeneity and the molecular diagnoses made are for emerging clinical conditions sharing characteristic features that overlap the DubS phenotype.
KW - Dubowitz syndrome
KW - exome sequencing
KW - genetic heterogeneity
KW - genome sequencing
KW - microarray
UR - http://www.scopus.com/inward/record.url?scp=85097746888&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.61926
DO - 10.1002/ajmg.a.61926
M3 - Article
AN - SCOPUS:85097746888
SN - 1552-4825
VL - 185
SP - 119
EP - 133
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 1
ER -